Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG’s Research and Development capabilities along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States.
Company Details
- Employees
- 1
- Address
- Has Granted Poltreg A New Patent Titled “method For Ex Vivo Expansion Of Regulatory T Cells.”
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://immuthera.bio/
- Keywords
- AvenCell.
Immuthera Questions
Immuthera's website is https://immuthera.bio/
Immuthera's LinkedIn profile is https://www.linkedin.com/company/immuthera
Immuthera has
1 employees.
View email and phone details for 1
employees at Immuthera.
Immuthera's industry is
Biotechnology Research
Immuthera's top competitors are
Xellsmart Bio,
Avencell,
Anocca,
Maxcyte, Inc.,
Antion Biosciences Sa,
Be Biopharma,
Tenaya Therapeutics,
Genevit,
Virocell Biologics,
Poltreg S.a..
Immuthera's categories are Biotechnology Research
